Companies: 10,795·Total market cap: $144.5T
Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOSNASDAQHealthcare● Active
$0.87
+$0.01(+0.64%)
Market Cap$5123882
P/E Ratio
52W High$7.95
52W Low$0.545
Overview

Vivos Therapeutics, Inc. (VVOS) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

vvos · stock forecast · 5 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 5 Wall Street analysts in the past 3 months

SellBuy

Buy

5 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
0
Sell
0
Strong Sell
0
Total: 5 · Buy rate: 100.0%

12-Month Price Target

High

$2.50

Consensus

$2.13

+144.8% upside

Low

$1.75

Median: $2.125 · Last Close: $0.87

The Vivos Therapeutics, Inc. (VVOS) analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month VVOS price target is $2.13, representing +144.8% upside from the current price of $0.87.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $2 (144.8%)

Consensus Target

$2.13

144.8% upside

High Target

$2.5

187.4%

Low Target

$1.75

101.1%

Current Price

$0.87

as of today

Based on analyst price targets, the VVOS stock price prediction for the next 12 months ranges from $1.75 to $2.5. The consensus VVOS price forecast of $2.13 implies 144.8% upside from the current price of $0.87.

Short-Term Price Prediction

Bear

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$0.915.00%

1-day model range: $0.9–$0.93. Peak: $0.93 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$0-50.0%
2028$0-62.5%
2029$0-67.2%
2030$0-69.2%
2031-70.2%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

43%0%57%
6Buy
0Neutral
8Sell
RSI (14)82.0Overbought
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · VVOS · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$0.75BUY
MA 10$0.71BUY
MA 20$0.68BUY
MA 50$0.88SELL
MA 100$1.21SELL
MA 200$2.02SELL
Current $VVOS · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.78BUY
EMA 10$0.73BUY
EMA 20$0.73BUY
EMA 50$0.88SELL
EMA 100$1.23SELL
EMA 200$1.82SELL
Current $VVOS · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Ascendiant Capital2026-06-04
Maintains
BuyBuy
Ascendiant Capital2026-04-22
Maintains
BuyBuy
HC Wainwright & Co.2026-04-17
Maintains
BuyBuy
Ascendiant Capital2025-12-03
Maintains
BuyBuy
Ascendiant Capital2025-09-09
Maintains
BuyBuy
Ascendiant Capital2025-04-15
Maintains
BuyBuy
Ascendiant Capital2024-11-20
Maintains
BuyBuy
Alliance Global Partners2024-11-19
Maintains
BuyBuy
Ascendiant Capital2024-08-20
Maintains
BuyBuy
Ascendiant Capital2023-01-17
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Vivos Therapeutics, Inc. (VVOS) stock. Of the recent 14 rating actions, 0 were upgrades and 0 were downgrades. 5 analysts currently cover VVOS.

Analyst Recommendation Trends

Buy ratings211
Hold ratings00
Sell ratings00

VVOS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$14M

↓ 32.3% YoY

Revenue Next Year

$15M

↑ 8.4% YoY

EPS This Year

$-5.91

EPS Next Year

$-2.02

↓ 65.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast VVOS EPS of $-5.91 for the current fiscal year, based on estimates from 1 analysts. The VVOS revenue forecast is $14M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The VVOS stock forecast is supported by two independent data sources: analyst consensus ratings from 5 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VVOS price target is $2.13 (+144.8% upside), with an analyst consensus of Buy.

The VVOS short-term stock prediction for tomorrow is $0.91 (+5.00%). The VVOS stock price prediction for 2027 estimates an average of $0. The VVOS stock prediction for 2030 projects a range of $0–$0.

Vivos Therapeutics, Inc. trades on NASDAQ under the ticker VVOS. The VVOS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

VVOS forecast · 8 questions

According to 5 Wall Street analysts, the average 12-month VVOS price target is $2.13, with a high forecast of $2.50 and a low of $1.75. The median price target is shown in the chart above when available. This implies +144.8% potential upside from the current price of $0.87.

VVOS price targetWhat is VVOS price targetVVOS analyst price targetVVOS 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.